Zacks Research Has Bullish Forecast for BHC FY2026 Earnings

Bausch Health Cos Inc. (NYSE:BHC – Free Report) – Stock analysts at Zacks Research upped their FY2026 earnings per share estimates for Bausch Health Cos in a research note issued to investors on Wednesday, November 18th. Zacks Research analyst Team now forecasts that the company will post earnings of $4.98 per share for the year, up from their previous forecast of $4.24. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.53 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q3 2028 earnings at $0.72 EPS and FY2028 earnings at $3.03 EPS.

Bausch Health Cos (NYSE:BHC – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.52. The business had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.72 billion. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%.

Several other research firms have also commented on BHC. Weiss Ratings reissued a “sell (d)” rating on shares of Bausch Health Cos in a research note on Thursday, October 29th. Jefferies Financial Group lifted their target price on shares of Bausch Health Cos from $6.50 to $8.00 and gave the company a “hold” rating in a report on Thursday, October 29th. Royal Bank Of Canada boosted their price target on Bausch Health Cos from $9.00 to $10.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 29th. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Finally, Barclays lifted their price objective on Bausch Health Cos from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 11th. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bausch Health Cos currently has a consensus rating of “Reduce” and an average target price of $8.75.

Read Our Latest Stock Report on Bausch Health Cos

Bausch Health Cos Price Performance

Shares of Bausch Health Cos stock opened at $8.57 on Friday. The company has a 50-day moving average of $6.75 and a 200 day moving average of $5.86. The firm has a market cap of $3.21 billion, a price-to-earnings ratio of -3.74 and a beta of 0.30. Bausch Health Cos has a 1 year low of $4.33 and a 1 year high of $9.04.

Institutional Trading of Bausch Health Cos

Institutional investors and hedge funds have recently modified their holdings of the business. Commonwealth Equity Services LLC raised its stake in shares of Bausch Health Cos by 22.7% in the third quarter. Commonwealth Equity Services LLC now owns 12,992 shares of the company’s stock worth $76,000 after purchasing an additional 2,400 shares during the last quarter. Cetera Investment Advisers boosted its position in shares of Bausch Health Cos by 15.5% during the third quarter. Cetera Investment Advisers now owns 19,407 shares of the company’s stock valued at $113,000 after buying an additional 2,608 shares during the last quarter. Roxbury Financial LLC purchased a new stake in shares of Bausch Health Cos during the third quarter valued at $28,000. Tacita Capital Inc purchased a new stake in shares of Bausch Health Cos during the second quarter valued at $29,000. Finally, Lazard Asset Management LLC increased its holdings in Bausch Health Cos by 15.5% in the 1st quarter. Lazard Asset Management LLC now owns 53,139 shares of the company’s stock worth $287,000 after buying an additional 7,114 shares in the last quarter. Institutional investors own 78.65% of the company’s stock.

Top Bausch Health Cos Stories

Here are a few of the latest stories about BHC:

  • Positive Sentiment: Zacks Research raised its FY2027 EPS estimate to $3.89 from $3.85 and increased estimates for several quarters, including Q4 2026 and Q1–Q2 2027. The revisions suggest slightly improved analyst expectations. MarketBeat analyst estimate updates
  • Positive Sentiment: Solta Medical, Bausch Health’s aesthetics business, said it has surpassed 10 million treatments worldwide across its portfolio, including Thermage, Fraxel and Clear + Brilliant. The milestone highlights adoption of its products, though no financial impact was disclosed. Solta Medical treatment milestone
  • Neutral Sentiment: Zacks Research maintained a Hold rating, indicating the estimate changes did not come with a more bullish recommendation. MarketBeat analyst estimate updates

About Bausch Health Cos

(Get Free Report)

Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics. Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.

Featured Articles

Earnings History and Estimates for Bausch Health Cos (NYSE:BHC)

Receive News & Ratings for Bausch Health Cos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Cos and related companies with MarketBeat.com's FREE daily email newsletter.